GlassScriptPhysician profile
Tracie White
NPI 1689336380
$2,959.65
in general payments reported to CMS, 2019-2025
25 companies · $1,215 in 2025
The $1,215 reported for 2025 was more than what 89% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $108 · 2022: $576 · 2023: $415 · 2024: $646 · 2025: $1,215.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,276.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,276.04 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $387.06 | 2021-2025 | Fasenra, Lokelma |
| Glaxosmithkline, LLC. | $224.19 | 2025 | Arexvy, Nucala |
| Pfizer INC. | $216.60 | 2024-2025 | |
| Novo Nordisk INC | $214.42 | 2022-2024 | Wegovy |
| Heartflow, INC. | $187.12 | 2022 | |
| Genzyme Corporation | $184.91 | 2023 | |
| Sun Pharmaceutical Industries INC. | $142.21 | 2025 | |
| Csl Behring | $123.80 | 2024 | Kcentra |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $115.88 | 2025 | Caplyta |
| Cipher Pharmaceuticals US LLC | $101.47 | 2025 | Natroba, Spinosad |
| Neurelis, INC. | $101.43 | 2025 | Valtoco |
| Otsuka America Pharmaceutical, INC. | $96.52 | 2024 | Rexulti |
| Janssen Pharmaceuticals, INC | $94.68 | 2024 | Xarelto |
| Mylan Specialty L.P. | $90.46 | 2022 | |
| E.R. Squibb & Sons, L.L.C. | $88.22 | 2025 | Cobenfy |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sumitomo Pharma America, INC. | $87.19 | 2023 | Gemtesa |
| Kyowa Kirin, INC. | $86.67 | 2025 | |
| Inspire Medical Systems, INC. | $84.95 | 2024 | Inspire |
| Acadia Pharmaceuticals INC | $74.99 | 2022 | |
| Merck Sharp & Dohme LLC | $71.68 | 2025 | Capvaxive |
| Daiichi Sankyo INC. | $60.57 | 2023 | |
| Phathom Pharmaceuticals, INC. | $53.97 | 2024 | Voquezna |
| Teva Pharmaceuticals USA, INC. | $38.46 | 2025 | Austedo Xr |
| Bayer Healthcare Pharmaceuticals INC. | $17.27 | 2025 | |
| Kowa Pharmaceuticals America, INC. | $14.93 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Tracie White listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.